These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 10634802)

  • 1. The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits.
    Bocan TM; Krause BR; Rosebury WS; Mueller SB; Lu X; Dagle C; Major T; Lathia C; Lee H
    Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):70-9. PubMed ID: 10634802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The combined effect of inhibiting both ACAT and HMG-CoA reductase may directly induce atherosclerotic lesion regression.
    Bocan TM; Krause BR; Rosebury WS; Lu X; Dagle C; Bak Mueller S; Auerbach B; Sliskovic DR
    Atherosclerosis; 2001 Jul; 157(1):97-105. PubMed ID: 11427208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice.
    Delsing DJ; Offerman EH; van Duyvenvoorde W; van Der Boom H; de Wit EC; Gijbels MJ; van Der Laarse A; Jukema JW; Havekes LM; Princen HM
    Circulation; 2001 Apr; 103(13):1778-86. PubMed ID: 11282910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology of the ACAT inhibitor avasimibe (CI-1011).
    Llaverías G; Laguna JC; Alegret M
    Cardiovasc Drug Rev; 2003; 21(1):33-50. PubMed ID: 12595916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of CI-976, an ACAT inhibitor, and selected lipid-lowering agents for antiatherosclerotic activity in iliac-femoral and thoracic aortic lesions. A biochemical, morphological, and morphometric evaluation.
    Bocan TM; Mueller SB; Uhlendorf PD; Newton RS; Krause BR
    Arterioscler Thromb; 1991; 11(6):1830-43. PubMed ID: 1931885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acyl-coenzyme A:cholesterol acyltransferase inhibitor, avasimibe, stimulates bile acid synthesis and cholesterol 7alpha-hydroxylase in cultured rat hepatocytes and in vivo in the rat.
    Post SM; Zoeteweij JP; Bos MH; de Wit EC; Havinga R; Kuipers F; Princen HM
    Hepatology; 1999 Aug; 30(2):491-500. PubMed ID: 10421659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs.
    Burnett JR; Wilcox LJ; Telford DE; Kleinstiver SJ; Barrett PH; Newton RS; Huff MW
    J Lipid Res; 1999 Jul; 40(7):1317-27. PubMed ID: 10393217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma cholesterol and limit atherosclerotic lesion development in the cholesterol-fed rabbit.
    Bocan TM; Mueller SB; Brown EQ; Lee P; Bocan MJ; Rea T; Pape ME
    Atherosclerosis; 1998 Jul; 139(1):21-30. PubMed ID: 9699888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-atherosclerotic properties of the acyl-coenzyme A:cholesterol acyltransferase inhibitor F 12511 in casein-fed New Zealand rabbits.
    Rival Y; Junquéro D; Bruniquel F; N'Guyen X; Fauré P; Pomiès JP; Degryse AD; Delhon A
    J Cardiovasc Pharmacol; 2002 Feb; 39(2):181-91. PubMed ID: 11791003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A specific 15-lipoxygenase inhibitor limits the progression and monocyte-macrophage enrichment of hypercholesterolemia-induced atherosclerosis in the rabbit.
    Bocan TM; Rosebury WS; Mueller SB; Kuchera S; Welch K; Daugherty A; Cornicelli JA
    Atherosclerosis; 1998 Feb; 136(2):203-16. PubMed ID: 9543090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statin therapy alone and in combination with an acyl-CoA:cholesterol O-acyltransferase inhibitor on experimental atherosclerosis.
    Worthley SG; Helft G; Corti R; Worthley MI; Chew DP; Fayad ZA; Zaman AG; Fallon JT; Fuster V; Badimon JJ
    Pathophysiol Haemost Thromb; 2007; 36(1):9-17. PubMed ID: 18332609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-atherogenic effects of the acyl-CoA:cholesterol acyltransferase inhibitor, avasimibe (CI-1011), in cultured primary human macrophages.
    Rodriguez A; Usher DC
    Atherosclerosis; 2002 Mar; 161(1):45-54. PubMed ID: 11882316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions.
    Tardif JC; Grégoire J; L'Allier PL; Anderson TJ; Bertrand O; Reeves F; Title LM; Alfonso F; Schampaert E; Hassan A; McLain R; Pressler ML; Ibrahim R; Lespérance J; Blue J; Heinonen T; Rodés-Cabau J;
    Circulation; 2004 Nov; 110(21):3372-7. PubMed ID: 15533865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracellular mechanisms mediating the inhibition of apoB-containing lipoprotein synthesis and secretion in HepG2 cells by avasimibe (CI-1011), a novel acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitor.
    Taghibiglou C; Van Iderstine SC; Kulinski A; Rudy D; Adeli K
    Biochem Pharmacol; 2002 Feb; 63(3):349-60. PubMed ID: 11853686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological profile of F 12511, (S)-2',3', 5'-trimethyl-4'-hydroxy-alpha-dodecylthioacetanilide a powerful and systemic acylcoenzyme A: cholesterol acyltransferase inhibitor.
    Junquero D; Oms P; Carilla-Durand E; Autin J; Tarayre J; Degryse A; Patoiseau J; Colpaert FC; Delhon A
    Biochem Pharmacol; 2001 Jan; 61(1):97-108. PubMed ID: 11137714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ACAT inhibitor avasimibe increases the fractional clearance rate of postprandial triglyceride-rich lipoproteins in miniature pigs.
    Burnett JR; Telford DE; Barrett PH; Huff MW
    Biochim Biophys Acta; 2005 Dec; 1738(1-3):10-8. PubMed ID: 16427354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of acyl-CoA cholesterol O-acyltransferase reduces the cholesteryl ester enrichment of atherosclerotic lesions in the Yucatan micropig.
    Bocan TM; Mueller SB; Uhlendorf PD; Brown EQ; Mazur MJ; Black AE
    Atherosclerosis; 1993 Mar; 99(2):175-86. PubMed ID: 8503946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HMG-CoA reductase inhibitor, fluvastatin, has cholesterol-lowering independent "direct" effects on atherosclerotic vessels in high cholesterol diet-fed rabbits.
    Mitani H; Egashira K; Kimura M
    Pharmacol Res; 2003 Nov; 48(5):417-27. PubMed ID: 12967585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ACAT inhibitor, CI-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters.
    Nicolosi RJ; Wilson TA; Krause BR
    Atherosclerosis; 1998 Mar; 137(1):77-85. PubMed ID: 9568739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets.
    Lee HT; Sliskovic DR; Picard JA; Roth BD; Wierenga W; Hicks JL; Bousley RF; Hamelehle KL; Homan R; Speyer C; Stanfield RL; Krause BR
    J Med Chem; 1996 Dec; 39(26):5031-4. PubMed ID: 8978833
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.